JP6892922B2 - 新規フェニルプロピオン酸誘導体及びその用途 - Google Patents
新規フェニルプロピオン酸誘導体及びその用途 Download PDFInfo
- Publication number
- JP6892922B2 JP6892922B2 JP2019531649A JP2019531649A JP6892922B2 JP 6892922 B2 JP6892922 B2 JP 6892922B2 JP 2019531649 A JP2019531649 A JP 2019531649A JP 2019531649 A JP2019531649 A JP 2019531649A JP 6892922 B2 JP6892922 B2 JP 6892922B2
- Authority
- JP
- Japan
- Prior art keywords
- oxy
- dihydro
- acid
- hex
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- YMTVRPSKVALNPR-JBWFSBJDSA-N CC#CC(CC(O)=O)c(cc1)cnc1O[C@H](CCc1c(cc2)-c(cn3)ccc3OC3COCC3)c1c2F Chemical compound CC#CC(CC(O)=O)c(cc1)cnc1O[C@H](CCc1c(cc2)-c(cn3)ccc3OC3COCC3)c1c2F YMTVRPSKVALNPR-JBWFSBJDSA-N 0.000 description 1
- 0 CC#CC(CC(O**)=O)c1csc(*C2c3c(*=*)cc(*c4c(*)c(*)nnc4-4)c-4c3CC2)cc1 Chemical compound CC#CC(CC(O**)=O)c1csc(*C2c3c(*=*)cc(*c4c(*)c(*)nnc4-4)c-4c3CC2)cc1 0.000 description 1
- QFYGPUAIMQUIOO-JTQLQIEISA-N CC#C[C@@H](CC(O)=O)c(cc1)ccc1O Chemical compound CC#C[C@@H](CC(O)=O)c(cc1)ccc1O QFYGPUAIMQUIOO-JTQLQIEISA-N 0.000 description 1
- BENPHURJTUUUSX-NSHDSACASA-N CC#C[C@@H](CC(OC)=O)c(cc1)ccc1O Chemical compound CC#C[C@@H](CC(OC)=O)c(cc1)ccc1O BENPHURJTUUUSX-NSHDSACASA-N 0.000 description 1
- UEOXKWFFLGYVKH-UHFFFAOYSA-N CCOC(C(C(OCC)=O)=Cc(cc1)ccc1O)=O Chemical compound CCOC(C(C(OCC)=O)=Cc(cc1)ccc1O)=O UEOXKWFFLGYVKH-UHFFFAOYSA-N 0.000 description 1
- KCFMBEJZQRQTAY-HHRIYVEFSA-N CCOC(CC(c(cc1)cnc1O[C@H](CCc1c(-c(cn2)ccc2O[C@H]2COCC2)cc2)c1c2F)C#CC)=O Chemical compound CCOC(CC(c(cc1)cnc1O[C@H](CCc1c(-c(cn2)ccc2O[C@H]2COCC2)cc2)c1c2F)C#CC)=O KCFMBEJZQRQTAY-HHRIYVEFSA-N 0.000 description 1
- RGHHSNMVTDWUBI-UHFFFAOYSA-N Oc1ccc(C=O)cc1 Chemical compound Oc1ccc(C=O)cc1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20160171541 | 2016-12-15 | ||
| KR10-2016-0171541 | 2016-12-15 | ||
| KR10-2017-0171228 | 2017-12-13 | ||
| KR1020170171228A KR102007633B1 (ko) | 2016-12-15 | 2017-12-13 | 신규 페닐 프로피온 산 유도체 및 이의 용도 |
| PCT/KR2017/014757 WO2018111012A1 (en) | 2016-12-15 | 2017-12-14 | Novel phenyl propionic acid derivatives and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020502111A JP2020502111A (ja) | 2020-01-23 |
| JP2020502111A5 JP2020502111A5 (OSRAM) | 2020-11-12 |
| JP6892922B2 true JP6892922B2 (ja) | 2021-06-23 |
Family
ID=62559593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531649A Active JP6892922B2 (ja) | 2016-12-15 | 2017-12-14 | 新規フェニルプロピオン酸誘導体及びその用途 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11225472B2 (OSRAM) |
| EP (1) | EP3555076B1 (OSRAM) |
| JP (1) | JP6892922B2 (OSRAM) |
| KR (1) | KR102007633B1 (OSRAM) |
| CN (1) | CN110049984B (OSRAM) |
| AU (1) | AU2017374460B2 (OSRAM) |
| BR (1) | BR112019012433A2 (OSRAM) |
| CA (1) | CA3042528C (OSRAM) |
| DK (1) | DK3555076T3 (OSRAM) |
| ES (1) | ES2948485T3 (OSRAM) |
| FI (1) | FI3555076T3 (OSRAM) |
| HU (1) | HUE062468T2 (OSRAM) |
| IL (1) | IL267239B (OSRAM) |
| MX (1) | MX2019007071A (OSRAM) |
| MY (1) | MY198292A (OSRAM) |
| PH (1) | PH12019501251A1 (OSRAM) |
| PL (1) | PL3555076T3 (OSRAM) |
| PT (1) | PT3555076T (OSRAM) |
| RS (1) | RS64259B1 (OSRAM) |
| RU (1) | RU2760266C2 (OSRAM) |
| SI (1) | SI3555076T1 (OSRAM) |
| WO (1) | WO2018111012A1 (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220112185A1 (en) * | 2016-12-15 | 2022-04-14 | Ildong Pharmaceutical Co., Ltd. | Novel phenyl propionic acid derivatives and uses thereof |
| KR102007633B1 (ko) * | 2016-12-15 | 2019-08-06 | 일동제약(주) | 신규 페닐 프로피온 산 유도체 및 이의 용도 |
| CN111712494A (zh) | 2018-02-13 | 2020-09-25 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| US12083118B2 (en) | 2018-03-29 | 2024-09-10 | Arbutus Biopharma Corporation | Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same |
| EP4600247A3 (en) | 2018-04-19 | 2025-11-19 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| KR20230159715A (ko) | 2018-07-13 | 2023-11-21 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| AU2019366355B2 (en) | 2018-10-24 | 2022-10-13 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| WO2021071837A1 (en) | 2019-10-07 | 2021-04-15 | Kallyope, Inc. | Gpr119 agonists |
| BR112022017039A2 (pt) | 2020-02-28 | 2022-11-16 | Kallyope Inc | Agonistas de gpr40 |
| JP2023526625A (ja) | 2020-05-19 | 2023-06-22 | キャリーオペ，インク． | Ａｍｐｋアクチベーター |
| CN116390925A (zh) | 2020-06-26 | 2023-07-04 | 卡尔优普公司 | Ampk活化剂 |
| EP4329756A1 (en) * | 2021-04-29 | 2024-03-06 | Ildong Pharmaceutical Co., Ltd. | Pharmaceutical composition comprising gpr40 agonist and sglt-2 inhibitor |
| EP4358958A1 (en) * | 2021-06-21 | 2024-05-01 | Yunovia, Co., Ltd. | Method of controlling blood sugar level and treatment of diabetes and related conditions |
| WO2023080299A1 (ko) * | 2021-11-08 | 2023-05-11 | 일동제약(주) | 페닐 프로피온 산 유도체의 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물 |
| KR20240084229A (ko) * | 2022-12-06 | 2024-06-13 | 유노비아 주식회사 | 안정성이 향상된 gpr40 효현제를 유효성분으로 포함하는 약제학적 조성물 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4594611B2 (ja) * | 2002-11-08 | 2010-12-08 | 武田薬品工業株式会社 | 受容体機能調節剤 |
| BRPI0508098A (pt) * | 2004-02-27 | 2007-07-17 | Amgen Inc | compostos, composições farmacêuticas e métodos para uso no tratamento de distúrbios metabólicos |
| CA2560111A1 (en) * | 2004-03-15 | 2005-09-22 | Takeda Pharmaceutical Company Limited | Aminophenylpropanoic acid derivative |
| NZ564130A (en) | 2005-06-02 | 2009-12-24 | Jenrin Discovery | N-propargyl-1-aminoindan compounds useful for treating obesity |
| EP1924546A1 (en) * | 2005-09-14 | 2008-05-28 | Amgen, Inc | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
| JP5055852B2 (ja) | 2006-06-21 | 2012-10-24 | 住友大阪セメント株式会社 | 鉄資源の回収方法 |
| US20120302566A1 (en) * | 2010-12-01 | 2012-11-29 | Boehringer Ingelheim International Gmbh | Indanyloxydihydrobenzofuranylacetic acids |
| JP2013147443A (ja) * | 2012-01-18 | 2013-08-01 | Daiichi Sankyo Co Ltd | β置換カルボン酸誘導体 |
| US8633182B2 (en) * | 2012-05-30 | 2014-01-21 | Boehringer Ingelheim International Gmbh | Indanyloxyphenylcyclopropanecarboxylic acids |
| JP6533778B2 (ja) * | 2013-09-26 | 2019-06-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｇｐｒ４０アゴニストとしてのインダニルオキシジヒドロベンゾフラニル酢酸誘導体を調製するための方法および中間体 |
| US10195178B2 (en) | 2016-04-11 | 2019-02-05 | Janssen Pharmaceutica Nv | GPR40 agonists in anti-diabetic drug combinations |
| KR102007633B1 (ko) * | 2016-12-15 | 2019-08-06 | 일동제약(주) | 신규 페닐 프로피온 산 유도체 및 이의 용도 |
| US20220112185A1 (en) * | 2016-12-15 | 2022-04-14 | Ildong Pharmaceutical Co., Ltd. | Novel phenyl propionic acid derivatives and uses thereof |
| EP4329756A1 (en) * | 2021-04-29 | 2024-03-06 | Ildong Pharmaceutical Co., Ltd. | Pharmaceutical composition comprising gpr40 agonist and sglt-2 inhibitor |
| EP4358958A1 (en) * | 2021-06-21 | 2024-05-01 | Yunovia, Co., Ltd. | Method of controlling blood sugar level and treatment of diabetes and related conditions |
| US20230022803A1 (en) * | 2021-06-25 | 2023-01-26 | Ildong Pharmaceutical Co., Ltd. | Novel crystalline form of gpr40 agonist |
-
2017
- 2017-12-13 KR KR1020170171228A patent/KR102007633B1/ko active Active
- 2017-12-14 SI SI201731367T patent/SI3555076T1/sl unknown
- 2017-12-14 BR BR112019012433A patent/BR112019012433A2/pt not_active Application Discontinuation
- 2017-12-14 WO PCT/KR2017/014757 patent/WO2018111012A1/en not_active Ceased
- 2017-12-14 RU RU2019121871A patent/RU2760266C2/ru active
- 2017-12-14 PL PL17880872.1T patent/PL3555076T3/pl unknown
- 2017-12-14 CA CA3042528A patent/CA3042528C/en active Active
- 2017-12-14 EP EP17880872.1A patent/EP3555076B1/en active Active
- 2017-12-14 IL IL267239A patent/IL267239B/en unknown
- 2017-12-14 ES ES17880872T patent/ES2948485T3/es active Active
- 2017-12-14 CN CN201780074801.4A patent/CN110049984B/zh not_active Expired - Fee Related
- 2017-12-14 MX MX2019007071A patent/MX2019007071A/es unknown
- 2017-12-14 AU AU2017374460A patent/AU2017374460B2/en not_active Ceased
- 2017-12-14 US US16/467,654 patent/US11225472B2/en active Active
- 2017-12-14 HU HUE17880872A patent/HUE062468T2/hu unknown
- 2017-12-14 PT PT178808721T patent/PT3555076T/pt unknown
- 2017-12-14 MY MYPI2019003388A patent/MY198292A/en unknown
- 2017-12-14 JP JP2019531649A patent/JP6892922B2/ja active Active
- 2017-12-14 FI FIEP17880872.1T patent/FI3555076T3/fi active
- 2017-12-14 RS RS20230456A patent/RS64259B1/sr unknown
- 2017-12-14 DK DK17880872.1T patent/DK3555076T3/da active
-
2019
- 2019-06-06 PH PH12019501251A patent/PH12019501251A1/en unknown
-
2021
- 2021-11-10 US US17/523,652 patent/US11731961B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6892922B2 (ja) | 新規フェニルプロピオン酸誘導体及びその用途 | |
| TWI843243B (zh) | 作為glp-1受體激動劑的化合物、包含其的藥物組成物及其用途 | |
| EP2695881B1 (en) | Guanidine compound | |
| TWI666201B (zh) | 稠環衍生物、其製備方法、中間體、藥物組合物及應用 | |
| TWI833781B (zh) | 新穎3,5-二取代吡啶及3,5-二取代噠嗪衍生物及其醫藥用途 | |
| JP7170996B2 (ja) | スルホンアミド誘導体またはその薬学的に許容される酸付加塩 | |
| KR20120003941A (ko) | 신규 갑상선 호르몬 β 수용체 작동약 | |
| TW201217386A (en) | Heterocyclic compound and use thereof | |
| WO2015000412A1 (zh) | 苯并环丁烯类衍生物、其制备方法及其在医药上的应用 | |
| WO2013154163A1 (ja) | 新規５－アリール－１，２－チアジナン誘導体 | |
| CN112457296B (zh) | 嘧啶类化合物及其制备方法 | |
| JP5331953B2 (ja) | 代謝性障害の治療のための３−アミノ−ピリジン誘導体 | |
| WO2021228215A1 (zh) | 可用作RORγ调节剂的联芳基类化合物 | |
| WO2021213476A1 (zh) | 一种吡唑并[1,5-a]吡啶类衍生物及其制备方法，组合物以及用途 | |
| WO2025021048A1 (zh) | 一类多环化合物及其用途 | |
| US20220112185A1 (en) | Novel phenyl propionic acid derivatives and uses thereof | |
| CN119836419A (zh) | 取代的四氢芳庚并[e]吲哚衍生物、其制备方法及其治疗用途 | |
| RU2747801C2 (ru) | Композиции для лечения легочного фиброза | |
| TW201920107A (zh) | 作為ttx-s阻斷劑之雙芳氧基衍生物 | |
| WO2024212742A1 (zh) | 一种glp-1r激动剂，其制备方法和应用 | |
| WO2024240231A1 (zh) | Fgfr2/3选择性抑制剂、药物组合物及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190613 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200629 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200702 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20201001 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210316 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210405 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210521 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210528 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6892922 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |